go to top
An employee of Chinese pharmaceutical giant Sinovac works in a lab An employee of Chinese pharmaceutical giant Sinovac works in a lab at a factory producing its vaccine for COVID-19, Beijing, Sept. 24, 2020 (AP photo by Ng Han Guan).

How China Is Trying to Capitalize on the COVID-19 Vaccine Race

, Wednesday, Dec. 2, 2020

Editor’s Note: Every Wednesday, WPR contributor Lavender Au and Assistant Editor Benjamin Wilhelm curate the week’s top news and expert analysis on China. Subscribers can adjust their newsletter settings to receive China Note by email every week.

The global race for COVID-19 vaccines has serious implications for how soon countries will be able to return to something resembling pre-pandemic normality. China has struck deals with more than a dozen countries to develop vaccines, including many with which it has close trade ties, amid questions about the vaccine trials and their eventual rollouts. ...

To read more,

enter your email address then choose one of the three options below.

Subscribe to World Politics Review and you'll receive instant access to 10,000+ articles in the World Politics Review Library, along with new comprehensive analysis every weekday . . . written by leading topic experts.